- Home
- STT vs ILMN Comparison
STT vs ILMN Comparison
Compare STT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STT
- ILMN
- Stock Information
- Founded
- STT 1792
- ILMN 1998
- Country
- STT United States
- ILMN United States
- Employees
- STT N/A
- ILMN N/A
- Industry
- STT Major Banks
- ILMN Medical Specialities
- Sector
- STT Finance
- ILMN Health Care
- Exchange
- STT Nasdaq
- ILMN Nasdaq
- Market Cap
- STT 32.3B
- ILMN 15.3B
- IPO Year
- STT N/A
- ILMN 2000
- Fundamental
- Price
- STT $116.90
- ILMN $122.44
- Analyst Decision
- STT Buy
- ILMN Hold
- Analyst Count
- STT 13
- ILMN 15
- Target Price
- STT $127.92
- ILMN $114.93
- AVG Volume (30 Days)
- STT 2.5M
- ILMN 2.0M
- Earning Date
- STT 10-17-2025
- ILMN 10-30-2025
- Dividend Yield
- STT 2.87%
- ILMN N/A
- EPS Growth
- STT 49.61
- ILMN N/A
- EPS
- STT 9.43
- ILMN 4.46
- Revenue
- STT $13,626,000,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- STT $7.99
- ILMN N/A
- Revenue Next Year
- STT $4.63
- ILMN $2.22
- P/E Ratio
- STT $12.39
- ILMN $27.45
- Revenue Growth
- STT 8.59
- ILMN N/A
- 52 Week Low
- STT $72.81
- ILMN $68.70
- 52 Week High
- STT $119.33
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- STT 54.34
- ILMN 68.75
- Support Level
- STT $113.83
- ILMN $94.00
- Resistance Level
- STT $119.33
- ILMN $124.08
- Average True Range (ATR)
- STT 2.62
- ILMN 5.01
- MACD
- STT 0.05
- ILMN 2.80
- Stochastic Oscillator
- STT 83.46
- ILMN 88.88
About STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $49 trillion in assets under custody and administration, and $5.1 trillion in assets under management, as of June 30, 2025, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.